Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 13/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706812 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL706813 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL10091584 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL31633433 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| Hydrochloric Acid SCHEMBL29353760 | 0.99 | PIM1 (0.98) | PIM1PIM2FLT3PIM3MEN1 | |
| Hydrochloric Acid SCHEMBL31090685 | 0.98 | PIM1 (0.97) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL10091583 | 0.97 | PIM1 (0.94) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL31434436 | 0.93 | PIM1 (0.87) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL10091766 | 0.92 | PIM1 (0.86) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL31434336 | 0.91 | PIM1 (0.84) | PIM1PIM2FLT3PIM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024160270-A1 | METHOD FOR SCREENING DRUG FOR TUMOR DISEASE, PROGRAM PRODUCT, HIGH-CONTENT IMAGING ANALYSIS SYSTEM, AND METHOD FOR ANALYZING PHASE SEPARATION CONDITIONS | 北京大学 | 2024-08-08 | — | — | WO | claimed |
| EP-3967307-A1 | USE OF PIM KINASE INHIBITORS TO AUGMENT THE EFFICACY OF ANTI-CD20 ANTIBODY-BASED THERAPIES IN HEMATOLOGIC MALIGNANCIES AND NON-MALIGNANT CONDITIONS | Instytut Hematologii I Transfuzologii (PL) | 2022-03-16 | — | — | EP | claimed |
| WO-2025247829-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR TREATING PROSTATE CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-04 | — | — | WO | disclosed |
| CN-120189418-A | Application of CX6258 in preparation of medicines for treating tumors | 南方医科大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-120189418-A | Application of CX6258 in preparation of medicines for treating tumors | 南方医科大学 | 2025-06-24 | — | — | CN | disclosed |
| US-12303515-B2 | PIM1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof | CITY UNIVERSITY OF HONG KONG (CN) | 2025-05-20 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-4520828-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | The Schepens Eye Research Institute, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20220288087-A1 | PIM1 INHIBITORS FOR USE IN TREATMENT OF VIRAL INFECTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CITY UNIVERSITY OF HONG KONG (CN) | 2022-09-15 | — | — | US | disclosed |
| US-11389440-B2 | PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | disclosed |
| US-11319320-B2 | PIM kinase inhibitor compositions, methods, and uses thereof | SNAP BIO, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3967307-A1 | USE OF PIM KINASE INHIBITORS TO AUGMENT THE EFFICACY OF ANTI-CD20 ANTIBODY-BASED THERAPIES IN HEMATOLOGIC MALIGNANCIES AND NON-MALIGNANT CONDITIONS | Instytut Hematologii I Transfuzologii (PL) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303515-B2 | PIM1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885FLT3 104/4885 |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | VEGFA, PGF, FLT4 | PIM1 3266/4885PIM2 3600/4885FLT3 365/4885 |
| US-20220288087-A1 | PIM1 INHIBITORS FOR USE IN TREATMENT OF VIRAL INFECTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885FLT3 104/4885 |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | PIM1 3266/4885PIM2 3600/4885FLT3 365/4885 |
| US-11319320-B2 | PIM kinase inhibitor compositions, methods, and uses thereof | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885FLT3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.